Author: Customer Service

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that results from the...

Martela Corporation, inside information, 10.12.2025, at 15:30 The development of revenue and order intake has been weaker than expected during the current quarter on Martela’s key market areas. The margin development on projects and deliveries has continued to be positive in the second half of the year, but the margin levels have developed slightly below previous expectations. Due to these reasons, Martela is lowering its full-year profit forecast. New guidance for 2025: Martela Group’s full-year 2025 revenue is estimated to reach EUR 91-93 million in 2025 (EUR 86.7 million in 2024). The operating result is estimated to be negative and the operating loss is estimated to be at the level of EUR 1.1-2.3 million (operating loss in 2024 was EUR 6.5 million). Previous guidance for 2025: Martela anticipates its revenue to increase...

THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the Journal of the Endocrine Society. ACSL5 is an enzyme encoded by the Acsl5 gene that plays a vital role in lipid metabolism and is the target of LX9851, the Company’s investigational non-incretin, oral, small molecule ACSL5 inhibitor. Animal model data showed that mice genetically modified to lack the ACSL5 gene exhibited favorable metabolic characteristics, including reduced body fat and conserved lean body mass. In March...

TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has completed release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules. “PharmAla is pleased to have completed this first batch of material of Australian-made materials in partnership with our colleagues at Cortexa. This material will continue to drive progress in the Australian market, as well as our ongoing operations globally,” said Farnoud Kazemzadeh, COO, PharmAla Biotech. “However, we are all the more excited to move forward into a very active production schedule for 2026 – including the development...

Platform Poised to Expand into Joint and Cartilage Repair HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has submitted a new patent application with the U.S. Patent and Trademark Office (USPTO) titled “Spheroids For Cartilage Repair” covering a proprietary fibroblast-derived therapy platform for use in orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration. The application, if granted, strengthens the protection for the Company’s novel fibroblast technology that...

2025 Achievements Lay Foundation for Accelerated 2026 Expansion NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) — IQSTEL Inc. (NASDAQ: IQST) (“IQSTEL”), a leading provider of innovative telecommunications and technology solutions, today announced highlights from its 2025 performance in a year‑end executive interview, underscoring achievements that have positioned the company for accelerated growth in 2026. The leadership team detailed how disciplined execution, liability management, and strategic investments in their partners strengthened the company’s foundation while expanding its portfolio of products and services. With organizational alignment and a clear roadmap in place, IQSTEL enters 2026 focused on organic growth, corporate expansion, and delivering enhanced value to clients, partners, and shareholders. The interview...

MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay...

MONTREAL, Dec. 10, 2025 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V:FPC) (“Falco” or the “Corporation”) is pleased to announce that it has initiated an update of the feasibility study for its flagship Horne 5 Project located in Rouyn-Noranda, Québec (the “Horne 5 Project” or the “Project”). Falco anticipates that this study will be completed in the second quarter of 2026 and that it will reflect the considerable potential of the Project considering the significant changes in commodity prices since the release of the feasibility study for the Project in 2021 (the “2021 Feasibility Study”). Having completed the public hearing process with the Office of Public Hearings on the Environment (Québec) last year, the Corporation continues to work toward receiving the necessary ministerial decree authorizing the Project in the coming...

WEST HOLLYWOOD, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave”) or (the “Company”) today announced that it has initiated the patent-application process for a planned series of patents with the goal of covering key technologies underlying Argus, the Company’s space-enabled, AI-driven counter-unmanned aircraft system (C-UAS) platform. This step follows the Company’s prior public statement that it planned to pursue patent protection for the Argus platform. VisionWave has now engaged its intellectual-property counsel and begun preparing an initial set of provisional patent applications focused on Argus’s core system architecture and enabling technologies. These include, among other elements, the SkyWeave™️ high-frequency (HF) AI-driven communications backbone; space- and...

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727,969 shares of common stock of the Company originally issued in February 2025 at an exercise price of $6.63 per share and 316,360 shares of common stock of the Company originally issued in August 2025 at an exercise price of $6.3219 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-286276)...